Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRAS<sup>G12C</sup> Inhibitor-Reference-Cited by-同舟云学术

Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRAS^G12C Inhibitor

Published:2022-10-19 Issue:11 Volume:26 Page:3115-3125
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Zhang Liang¹^ORCID,Griffin Daniel J.¹^ORCID,Beaver Matthew G.¹^ORCID,Blue Laura E.²,Borths Christopher J.¹^ORCID,Brown Derek B.³^ORCID,Caille Seb³^ORCID,Chen Ying⁴,Cherney Alan H.⁴^ORCID,Cochran Brian M.⁴,Colyer John T.³,Corbett Michael T.³^ORCID,Correll Tiffany L.⁵,Crockett Richard D.⁴,Dai Xi-Jie¹^ORCID,Dornan Peter K.¹^ORCID,Farrell Robert P.⁴,Hedley Simon J.⁴,Hsieh Hsiao-Wu¹^ORCID,Huang Liang³,Huggins Seth³,Liu Min⁶,Lovette Michael A.³^ORCID,Quasdorf Kyle³^ORCID,Powazinik William¹,Reifman Jonathan³,Robinson Jo Anna³,Sangodkar Rahul P.¹^ORCID,Sharma Sonika¹,Kumar Srividya Sharvan¹,Smith Austin G.³^ORCID,St-Pierre Gabrielle³^ORCID,Tedrow Jason S.⁴^ORCID,Thiel Oliver R.¹^ORCID,Truong Jonathan V.¹,Walker Shawn D.¹,Wei Carolyn S.³,Wilsily Ashraf⁴^ORCID,Xie Yong⁵,Yang Ning⁵,Parsons Andrew T.¹^ORCID

Affiliation:

1. Pivotal & Commercial Synthetics, Amgen, Inc., 360 Binney St., Cambridge, Massachusetts02142, United States

2. Pre-Pivotal Attribute Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California91320, United States

3. Pivotal & Commercial Synthetics, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California91320, United States

4. Pre-Pivotal Drug Substance Technologies, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California91320, United States

5. Pivotal Attribute Sciences, Amgen, Inc., 360 Binney St., Cambridge, Massachusetts02142, United States

6. Pivotal Attribute Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California91320, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.2c00249

Reference15 articles.

1. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

2. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

3. Axial Chirality in the Sotorasib Drug Substance, Part 1: Development of a Classical Resolution to Prepare an Atropisomerically Pure Sotorasib Intermediate

4. Parsons, A. T.; Cochran, B. M.; Powazinik, IV, W.; Caporini, M. A. Improved Synthesis of Key Intermediate of KRAS G12C Inhibitor Compound. WO 2020102730 A1, May 22, 2020.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a Practical Telescoped Process to Prepare (P)-7-(2-Amino-6-fluorophenyl)-4-hydroxy-6-(trifluoromethyl)pyrido[3,4-d]pyrimidin-8(7H)-one: a Key Intermediate of KRAS^G12C Inhibitor GH35;Organic Process Research & Development;2024-09-13

2. Fit-for-Purpose Synthesis of a KRAS^G12C Covalent Inhibitor, via a Diastereoselective Hayashi Arylation;Organic Process Research & Development;2024-07-22

3. An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023);Journal of Medicinal Chemistry;2024-07-12

4. Flow Chemistry and Continuous Processing: More Mainstream than Ever!;Organic Process Research & Development;2024-05-17

5. Cryogen‐free 400‐MHz nuclear magnetic resonance spectrometer as a versatile tool for pharmaceutical process analytical technology;Magnetic Resonance in Chemistry;2024-02-18